Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-012252
Filing Date
2025-02-12
Accepted
2025-02-12 17:02:05
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7292
2 EXHIBIT 1 tm255748d2_ex99-1.htm EX-99.1 36146
  Complete submission text file 0001104659-25-012252.txt   45093
Mailing Address LICHTSTRASSE 35 CH-4002 BASEL V8
Business Address LICHTSTRASSE 35 CH-4002 BASEL V8 212-830-2474
NOVARTIS PHARMA AG (Filed by) CIK: 0001030617 (see all company filings)

Type: SCHEDULE 13G/A

Mailing Address 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121
Business Address 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121 (858) 465-6511
Erasca, Inc. (Subject) CIK: 0001761918 (see all company filings)

EIN.: 831217027 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92728 | Film No.: 25615863
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)